<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Neuropsychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Neuropsychopharmacol</journal-id><journal-id journal-id-type="publisher-id">ijnp</journal-id><journal-title-group><journal-title>International Journal of Neuropsychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">1461-1457</issn><issn pub-type="epub">1469-5111</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5616698</article-id><article-id pub-id-type="doi">10.1093/ijnp/pyw043.101</article-id><article-id pub-id-type="publisher-id">pyw043.101</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Sunday Abstracts</subject></subj-group></subj-group></article-categories><title-group><article-title>PS101. Oral Ketamine for Treatment Resistant Major Depression &#x02013; A double blind randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Domany</surname><given-names>Yoav</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bleich-Cohen</surname><given-names>Maya</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stoppelman</surname><given-names>Nadav</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hendler</surname><given-names>Talma</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tarrasch</surname><given-names>Ricardo</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schreiber</surname><given-names>Shaul</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Meidan</surname><given-names>Roi</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sharon</surname><given-names>Haggai</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Tel Aviv Sourasky Medical Center, Israel</aff><pub-date pub-type="collection"><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub" iso-8601-date="2016-05-27"><day>27</day><month>5</month><year>2016</year></pub-date><volume>19</volume><issue>Suppl 1</issue><fpage seq="f">35</fpage><lpage>35</lpage><permissions><copyright-statement>&#x000a9; The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</copyright-statement><copyright-year>2016</copyright-year></permissions><self-uri xlink:href="pyw043.101.pdf"/><counts><page-count count="1"/></counts></article-meta></front><body><p>
<bold>Abstract</bold>
</p><p>
<bold>Background:</bold> Major depression is a devastating common disorder. Current pharmacotherapy relies on the monoaminergic theory, and requires a substantial time for full therapeutic effect. Regrettably, about 40% fail to attain remission, defined as Treatment Resistant Depression (TRD). Recently, intravenous ketamine has been shown to provide rapid, short lived, amelioration of TRD. We aimed to assess the clinical efficacy and safety of oral ketamine for TRD.</p><p>
<bold>Methods:</bold> In a double-blind, randomized, placebo-controlled trial 27 TRD outpatients received either oral ketamine or placebo for 21 days. Patients were evaluated pre-trial and after 21 days. The main outcome measure was the change in Montgomry Asberg Depression Rating Scale- (MADRS) score.</p><p>
<bold>Result</bold>: 14 subjects were randomized to the ketamine group, and 13 to the placebo group. Of these, 12 and 9 respectably completed the study. No significant differences were obtained at time zero. A significant reduction of 13.4 points of the MADRS score was obtained after 21 days in the ketamine group (p=0.003) while a nonsignificant reduction of 2.9 was observed in the placebo group. Four subjects (33%) attained remission (MADRS &#x02264;10) in the ketamine group compared to none in the placebo group. No serious side effects were reported.</p><p>
<bold>Conclusion:</bold> In this study, sub-anesthetic oral ketamine produced rapid amelioration of depressive symptoms in ambulatory TRD patients, and was well tolerated. The results of this study suggest that oral ketamine may hold significant promise in the care of TRD.</p></body></article>